Shares of Anthem Biosciences listed on the stock market on Monday, July 21, making a strong market debut. The company’s shares opened at Rs 723.05 on the NSE and Rs 723.10 on the BSE. This was about 27% higher than its issue price of Rs 570.
The company launched its initial public offering (IPO) from July 14 to July 16. The total size of the IPO was Rs 3,395.79 crore. It received a strong response from all kinds of investors and was subscribed 67.42 times in total.
Investors showed keen interest in the IPO. It got bids for 281.49 crore shares, while only 4.17 crore shares were available for sale. The retail portion was subscribed 5.98 times. Non-institutional investors (NII) subscribed 44.70 times, and the qualified institutional buyers (QIBs) category was the most active, subscribing 192.80 times.
Before the listing, market watchers were expecting a higher debut based on the grey market premium (GMP).
As of July 20, the GMP stood at Rs 177 per share. Based on this, the expected listing price was around Rs 747, which would have meant a 31% gain from the issue price of Rs 570.
However, the stock opened slightly below this expected level, with a gain of nearly 27%. Market experts often track GMP to get an idea of investor mood and future expectations from the company, although it is not always accurate.
Anthem Biosciences is a Bengaluru-based company involved in contract research and manufacturing. With its successful market debut, it has added itself to the list of companies that have seen good interest from investors in 2025 so far.
– Ends
Source link
[ad_3]
